Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Resmetirom, already approved by the FDA for adults with non-cirrhotic MASH and stage F2F3 fibrosis, is ideal for lean or weight-stable patients with progressive fibrogenesis or atherogenic dyslipidemia
Moreover, roughly one in three of the more than 1,400 participants lost at least a quarter of their total body weight
However, individual European countries then negotiate pricing and reimbursement, which adds another 6 to 18 months before the drug is actually available at pharmacies in each country
We know that adherence to a medical regimen is not great
Pioglitazone Safety and efficacy of pioglitazone in pediatric patients have not been established
US$ 24.97
US$ 20.27
US$ 26.55
US$ 22.51
US$ 22.02
US$ 26.55
